Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Polascik

Showing results (1-10 of 315) with videos related to

Pageof 32
Sort By:
Drug Design, Development and Therapy|November 19, 2009
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastasesThomas J Polascik
The Journal of Urology|December 4, 2019
Editorial CommentThomas J Polascik
The Journal of Urology|January 4, 2021
Editorial CommentThomas J Polascik
Clinical Advances in Hematology & Oncology : H&O|March 8, 2019
The use of multiparametric MRI in diagnosis and active surveillance of prostate cancerThomas J Polascik
Current Opinion in Urology|March 17, 2015
Focal therapy of prostate cancer: making steady progress toward a first-line image-guided treatment modalityThomas J Polascik
The Journal of Urology|May 7, 2021
Editorial CommentThomas J Polascik
The Journal of Urology|August 31, 2019
Editorial CommentThomas J Polascik
Urology|September 14, 2010
Editorial commentMatvey Tsivian, Thomas J Polascik
BJU International|July 25, 2013
Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine studyMatvey Tsivian, Thomas J Polascik
European Urology|February 12, 2018
Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative TherapyAlireza Aminsharifi, Thomas J Polascik
Pageof 32

Showing results (1-10 of 315) with videos related to

Sort By:
Pageof 32
Drug Design, Development and Therapy|November 19, 2009
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastasesThomas J Polascik
The Journal of Urology|December 4, 2019
Editorial CommentThomas J Polascik
The Journal of Urology|January 4, 2021
Editorial CommentThomas J Polascik
Clinical Advances in Hematology & Oncology : H&O|March 8, 2019
The use of multiparametric MRI in diagnosis and active surveillance of prostate cancerThomas J Polascik
Current Opinion in Urology|March 17, 2015
Focal therapy of prostate cancer: making steady progress toward a first-line image-guided treatment modalityThomas J Polascik
The Journal of Urology|May 7, 2021
Editorial CommentThomas J Polascik
The Journal of Urology|August 31, 2019
Editorial CommentThomas J Polascik
Urology|September 14, 2010
Editorial commentMatvey Tsivian, Thomas J Polascik
BJU International|July 25, 2013
Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine studyMatvey Tsivian, Thomas J Polascik
European Urology|February 12, 2018
Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative TherapyAlireza Aminsharifi, Thomas J Polascik
Pageof 32